Passive Skin Permeation Enhancement

Transdermal and Topical Drug Delivery: Principles and Practice

Volumn , Issue , 2012, Pages 23-42

  Lane, Majella E ^b   Santos, Paulo ^c   Watkinson, Adam C ^a   Hadgraft, Jonathan ^b  

^a Storith Consulting Limited Kent   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Fundamental biophysical studies, and penetration enhancers; Passive skin permeation enhancement, water loss prevention; Thermodynamically unstable formulations, chemical penetration enhancers

Indexed keywords

EID: 84869497497     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118140505.ch2     Document Type: Chapter

References (108)

1. Washington C, Washington N. Drug delivery to the skin. In: Wilson CG, Washington N, eds. Physiological Pharmaceutics: Biological Barriers to Drug Absorption, 1st ed. Ellis Horwood, Chichester, 1989; 109-120.
2. Trommer H, Neubert RH. Overcoming the stratum corneum: The modulation of skin penetration. A review. Skin Pharmacol Physiol 2006; 19: 106-121.
3. Scheuplein RJ. Permeability of the skin. Physiol Rev 1971; 51: 702-747.
4. Barry BW. Lipid-protein-partition theory of skin penetration enhancement. J Control Release 1991; 15: 237-248.
5. Roberts MS. Targeted drug delivery to the skin and deeper tissues: Role of physiology, solute structure and disease. Clin Exp Pharmacol Physiol 1997; 24: 874-879.
6. Roberts MS, Cross SE, Pellett MA. Skin transport. In: Walters KA, ed. Dermatological and Transdermal Formulations. Marcel Dekker, Inc, New York, 2002; 89-195.
7. Albery WJ, Hadgraft J. Percutaneous absorption: In vivo experiments. J Pharm Pharmacol 1979; 31: 140-147.
8. Hadgraft J. Skin deep. Eur J Pharm Biopharm 2004; 58: 291-299.
9. Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Deliv Rev 1996; 18: 295-301.
10. Egelrud T. Desquamation in the stratum corneum. Acta Derm Venereol Supp 2000; 208: 44-45.
11. Hadgraft J. Structure activity relationships and percutaneous absorption. J Control Release 1991; 15: 221-226.
12. Cross SE, Magnusson BM, Winckle G, Anissimov Y, Roberts MS. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. J Invest Dermatol 2003; 120: 759-764.
13. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J 1975; 21: 985-996.
14. Albery WJ, Guy RH, Hadgraft J. Percutaneous absorption: Transport in the dermis. Int J Pharm 1983; 15: 125-148.
15. Crank J. The diffusion equations. In: Crank J, ed. The Mathematics of Diffusion. Clarendon Press, Oxford, 1975; 1-10.
16. Scheuplein RJ, Blank IH, Brauner GJ, MacFarlane DJ. Percutaneous absorption of steroids. J Invest Dermatol 1969; 52: 63-70.
17. Hadgraft J. Skin, the fi nal frontier. Int J Pharm 2001; 224: 1-18.
18. Vecchia BE, Bunge AL. Evaluating the transdermal permeability of chemicals. In: Guy RH, Hadgraft J, eds. Transdermal Drug Delivery, 2nd ed., Revised and Expanded. Marcel Dekker, New York, 2003; 25-55.
19. Hadgraft J, Valenta C. pH, pKa and dermal delivery. Int J Pharm 2000; 200: 243-247.
20. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-114.
21. Mitragotri S. Breaking the skin barrier. Adv Drug Deliv Rev 2004; 56: 555-716.
22. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184: 1-6.
23. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1960; 11: 85-97.
24. Davis AF. Topical drug release system. U.S. Patent 4,767,751. 1988.
25. James KC. Solutions and solubility. In: James KC, ed. Solubility and Related Properties. Marcel Dekker, New York, 1986; 1-52.
26. Davis A, Gyurik RJ, Hadgraft J, Pellett MA, Walters KA. Formulation strategies for modulating skin permeation. In: Walters KA, ed. D ermatological and Transdermal Formulations. Marcel Dekker, New York, 2002; 271-317.
27. Yalkowsky SH. Solubilization of drugs by cosolvents. In: Yalkowsky SH, Roseman TJ, eds. Techniques of Solubilization of drugs. Marcel Dekker, New York, 1981; 91-134.
28. Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int J Pharm 1991; 76: 1-8.
29. Dias MMR, Raghavan SL, Pellett MA, Hadgraft J. The effect of beta-cyclodextrins on the permeation of diclofenac from supersaturated solutions. Int J Pharm 2003; 263: 173-181.
30. Iervolino M, Cappello B, Raghavan SL, Hadgraft J. Penetration enhancement of ibuprofen from supersaturated solutions through human skin. Int J Pharm 2001; 212: 131-141.
31. Iervolino M, Raghavan SL, Hadgraft J. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000; 198: 229-238.
32. Pellett MA, Castellano S, Hadgraft J, Davis AF. The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro. J Control Release 1997; 46: 205-214.
33. Pellett MA, Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 2. Piroxicam Int J Pharm 1994; 111: 1-6.
34. Raghavan SL, Kiepfer B, Davis AF, Kazarian SG, Hadgraft J. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001; 221: 95-105.
35. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm 2000; 193: 231-237.
36. Watkinson AC, Brain KR, Walters KA. The penetration of ibuprofen through human skin in vitro: Vehicle, enhancer and pH effects. In: Brain KR, James V, Walters KA, eds. Prediction of Percutaneous Penetration. STS Publishing, Cardiff, 1993; 335-341.
37. Leveque N, Raghavan SL, Lane ME, Hadgraft J. Use of a molecular form technique for the penetration of supersaturated solutions of salicylic acid across silicone membranes and human skin in vitro. Int J Pharm 2006; 318: 49-54.
38. Raghavan SL, Schuessel K, Davis A, Hadgraft J. Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems. Int J Pharm 2003; 261: 153-158.
39. Kemken J, Ziegler A, Müller BW. Infl uence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res 1992; 9: 554-558.
40. Coldman MF, Poulsen BJ, Higuchi T. Enhancement of percutaneous absorption by the use of volatile: Nonvolatile systems as vehicles. J Pharm Sci 1969; 58: 1098-1102.
41. Morgan TM, O'Sullivan HM, Reed BL, Finnin BC. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J Pharm Sci 1998; 87: 1226-1228.
42. Morgan TM, Parr RA, Reed BL, Finnin BC. Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. J Pharm Sci 1998; 87: 1219-1225.
43. Henmi T, Fujii M, Kikuchi K, Yamanobe N, Matsumoto M. Application of an oily gel formed by hydrogenated soybean phospholipids as a percutaneous absorption-type ointment base. Chem Pharm Bull 1994; 42: 651-655.
44. Davis AF, Hadgraft J. Supersaturated solutions as topical drug delivery systems. In: Walters KA, Hadgraft J, eds. Pharmaceutical Skin Penetration Enhancement. Marcel Dekker, New York, 1993; 243-267.
45. Ma X, Taw J, Chiang C-M. Control of drug crystallization in transdermal matrix system. Int J Pharm 1996; 142: 115-119.
46. Moser K, Kriwet K, Kalia YN, Guy RH. Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery. Int J Pharm 2001; 224: 169-176.
47. Chiang CM, Flynn GL, Weiner ND, Szpunar GJ. Bioavailability assessment of topical delivery systems: Effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations. Int J Pharm 1989; 55: 229-236.
48. Frank FC. The infl uence of dislocations on crystal growth. Discuss Faraday Soc 1949; 5: 48-54.
49. Pellett MA, Raghavan SL, Hadgraft J, Davis AF. The application of supersaturated systems to percutaneous drug delivery. In: Guy RH, Hadgraft J, eds. Transdermal Drug Delivery, 2nd ed. Marcel Dekker, New York, 2003; 305-326.
50. Kondo S, Yamanaka C, Sugimoto I. Enhancement of transdermal delivery by superfl uous thermodynamic potential. III. Percutaneous absorption of nifedipine in rats. J Pharmaco-Biodyn 1987; 10: 743-749.
51. Kondo S, Sugimoto I. Enhancement of transdermal delivery by superfl uous thermodynamic potential. I. Thermodynamic analysis of nifedipine transport across the lipoidal barrier. J Pharmaco-Biodyn 1987; 10: 587-594.
52. Kondo S, Yamasaki-Konishi H, Sugimoto I. Enhancement of transdermal delivery by superfl uous thermodynamic potential. II. In vitro-in vivo correlation of percutaneous nifedipine transport. J Pharmaco-Biodyn 1987; 10: 662-668.
53. Raghavan SL, Trividic A, Davis AF, Hadgraft J. Crystallization of hydrocortisone acetate: Infl uence of polymers. Int J Pharm 2001; 212: 213-221.
54. Megrab NA, Williams AC, Barry BW. Oestradiol permeation through human skin and silastic membrane: Effects of propylene glycol and supersaturation. J Control Release 1995; 36: 277-294.
55. Pellett MA, Roberts MS, Hadgraft J. Supersaturated solutions evaluated with an in vitro stratum corneum tape stripping technique. Int J Pharm 1997; 151: 91-98.
56. Marjukka Suhonen TA, Bouwstra J, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 1999; 59: 149-161.
57. Karande P. Principles of penetration. Nat Rev Drug Discov 2005; 4: 372-373.
58. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc Nat Acad Sci 2005; 102: 4688-4693.
59. Finnin BC, Morgan TM. Transdermal penetration enhancers: Applications, limitations, and potential. J Pharm Sci 1999; 88: 955-958.
60. Traversa B. Enhancement of the percutaneous absorption of the opioid analgesic fentanyl. PhD Thesis. Department of Pharmaceutics, Victorian College of Pharmacy, Monash University, Melbourne, 2005.
61. Walters KA, Roberts MS. The structure and function of skin. In: Walters KA, ed. Dermatological and Transdermal Formulations. Marcel Dekker, New York, 2002; 1-39.
62. Hadgraft J, Williams DG, Allan G. Azone: Mechanisms of action and clinical effect. In: Walters KA, Hadgraft J, eds. Pharmaceutical Skin Penetration Enhancement. Marcel Dekker, New York, 1993; 175-197.
63. Lambert WJ, Higuchi WI, Knutson K, Krill SL. Dose-dependent enhancement effects of Azone on skin permeability. Pharm Res 1989; 6: 798-803.
64. Harrison JE, Groundwater PW, Brain KR, Hadgraft J. Azone(R) induced fl uidity in human stratum corneum. A Fourier transform infrared spectroscopy investigation using the perdeuterated analogue. J Control Release 1996; 41: 283-290.
65. Harrison JE, Watkinson AC, Green DM, Hadgraft J, Brain K. The relative effect of Azone and transcutol on permeant diffusivity and solubility in human stratum corneum. Pharm Res 1996; 13: 542-546.
66. Hadgraft J, Peck J, Williams DG, Pugh WJ, Allan G. Mechanisms of action of skin penetration enhancers/retarders: Azone and analogues. Int J Pharm 1996; 141: 17-25.
67. Aungst BJ, Rogers NJ, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm 1986; 33: 225-234.
68. Bouwstra JA, Peschier LJC, Brussee J, Bodde HE. Effect of N-alkyl-azocycloheptan-2-ones including Azone on the thermal behaviour of human stratum corneum. Int J Pharm 1989; 52: 47-54.
69. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004; 56: 603-618.
70. Golden GM, McKie JE, Potts RO. Role of stratum corneum lipid fl uidity in transdermal drug fl ux. J Pharm Sci 1987; 76: 25-28.
71. Chien YW, Xu H, Chiang C-C, Huang Y-C. Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability. Pharm Res 1988; 5: 103-106.
72. Ogiso T, Shintani M. Mechanism for the enhancement effect of fatty acids on the percutaneous absorption of propranolol. J Pharm Sci 1990; 79: 1065-1071.
73. Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res 1991; 8: 350-354.
74. Hansen C. Hansen Solubility Parameters: A user's Handbook. CRC Press, Boca Raton, FL, 2000; 1-24.
75. Liron Z, Cohen S. Percutaneous absorption of alkanoic acids II: Application of regular solution theory. J Pharm Sci 1984; 73: 538-542.
76. Wotton PK, Mollgaard B, Hadgraft J, Hoelgaard A. Vehicle effect on topical drug delivery. III. Effect of Azone on the cutaneous permeation of metronidazole and propylene glycol. Int J Pharm 1985; 24: 19-26.
77. Puglia C, Bonina F, Trapani G, Franco M, Ricci M. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydro-alcoholic gel formulations. Int J Pharm 2001; 228: 79-87.
78. Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987; 6: 85-97.
79. Barry BW, Bennett SL. Effect of penetration enhancers on the permeation of mannitol, hydrocortisone and progesterone through human skin. J Pharm Pharmacol 1987; 39: 535-546.
80. Cornwell PA, Barry BW, Bouwstra JA, Gooris GS. Modes of action of terpene penetration enhancers in human skin; Differential scanning calorimetry, small-angle X-ray diffraction and enhancer uptake studies. Int J Pharm 1996; 127: 9-26.
81. Brinkmann I, Muller-Goymann CC. An attempt to clarify the infl uence of glycerol, propylene glycol, isopropyl myristate and a combination of propylene glycol and isopropyl myristate on human stratum corneum. Pharmazie 2005; 60: 215-220.
82. Goodman M, Barry BW. Lipid-protein-partitioning (LPP) theory of skin enhancer activity: Finite dose technique. Int J Pharm 1989; 57: 29-40.
83. Sato K, Sugibayashi K, Morimoto Y. Effect and mode of action of aliphatic esters on the in vitro skin permeation of nicorandil. Int J Pharm 1988; 43: 31-40.
84. Seki T, Sugibayashi K, Juni K, Morimoto Y. Percutaneous absorption enhancer applied to membrane permeation-controlled transdermal delivery of nicardipine hydrochloride. Drug Des Deliv 1989; 4: 69-75.
85. Mollgaard B. Synergistic effect in percutaneous enhancement. In: Walters KA, Hadgraft J, eds. Pharmaceutical Skin Penetration Enhancement. Marcel Dekker, New York, 1993; 229-242.
86. Leopold CS, Lippold BC. An attempt to clarify the mechanism of the penetration enhancing effects of lipophilic vehicles with differential scanning calorimetry (DSC). J Pharm Pharmacol 1995; 47: 276-281.
87. Hirvonen J, Rajala R, Vihervaara P, Laine E, Paronen P, Urtti A. Mechanism and reversibility of penetration enhancer action in the skin. Eur J Pharm Biopharm 1995; 40: 81-85.
88. Brinkmann I, Muller-Goymann CC. Role of isopropyl myristate, isopropyl alcohol and a combination of both in hydrocortisone permeation across the human stratum corneum. Skin Pharmacol Appl Skin Physiol 2003; 16: 393-404.
89. Alberti I, Kalia YN, Naik A, Bonny J-D, Guy RH. Effect of ethanol and isopropyl myristate on the availability of topical terbinafi ne in human stratum corneum, in vivo. Int J Pharm 2001; 219: 11-19.
90. Kraus CA. The ion pair concept: Its evolution and some applications. J Phys Chem 1956; 60: 129-141.
91. Pardo A, Shin Y, Cohen S. Kinetics of transdermal penetration of an organic ion pair. Physostigmine salicylate. J Pharm Sci 1992; 81: 990-995.
92. Hadgraft J, Walters KA, Wotton PK. Facilitated percutaneous absorption: A comparison and evaluation of two in vitro models. Int J Pharm 1986; 32: 257-263.
93. Langguth P, Mutschler E. Lipophilization of hydrophilic compounds: Consequences on transepidermal and intestinal transport of trospium chloride. Arzneimittelforschung 1987; 37: 1362-1366.
94. Green PG, Hadgraft J, Wolff M. Physicochemical aspects of the transdermal delivery of bupranolol. Int J Pharm 1989; 55: 265-269.
95. Kurihara-Bergstrom T, Lin P. Enhanced in vitro skin transport of ionized terbutaline using its sulfate salt form in aqueous isopropanol. STP Pharma Sci 1991; 1: 52-59.
96. Nash RA, Mehta DB, Matias JR, Orentreich N. The possibility of lidocaine ion pair absorption through excised hairless mouse skin. Skin Pharmacol 1992; 5: 160-170.
97. Trotta M, Pattarino F, Gasco MR. Infl uence of counter ions on the skin penetration of methotrexate from water-oil microemulsions. Pharm Acta Helv 1996; 71: 135-140.
98. Nyqvist-Mayer AA, Brodin AF, Frank SG. Drug release studies on an oil-water emulsion based on a eutectic mixture of lidocaine and prilocaine as the dispersed phase. J Pharm Sci 1986; 75: 365-373.
99. Stott PW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: Enhanced permeation of a model drug, ibuprofen. J Control Release 1998; 50: 297-308.
100. Stott PW, Williams AC, Barry BW. Mechanistic study into the enhanced transdermal permeation of a model ß-blocker, propranolol, by fatty acids: A melting point depression effect. Int J Pharm 2001; 219: 161-176.
101. Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C. Effect of concentration and degree of saturation of topical fl uocinonide formulations on in vitro membrane transport and in vivo availability on human skin. Pharm Res 1999; 16: 909-915.
102. Moser K, Kriwet K, Froehlich C, Naik A, Kalia YN, Guy RH. Permeation enhancement of a highly lipophilic drug using supersaturated systems. J Pharm Sci 2001; 90: 607-616.
103. Moser K, Kriwet K, Froehlich C, Kalia YN, Guy RH. Supersaturation: Enhancement of skin penetration and permeation of a lipophilic drug. Pharm Res 2001; 18: 1006-1011.
104. Moser K, Kriwet K, Kalia YN, Guy RH. Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J Control Release 2001; 73: 245-253.
105. Tanaka S, Takashima Y, Murayama H, Tsuchiya S. Studies on drug release from ointments. V. Release of hydrocortisone butyrate propionate from topical dosage forms to silicone rubber. Int J Pharm 1985; 27: 29-38.
106. Fang J-Y, Kuo C-T, Huang Y-B, Wu P-C, Tsai Y-H. Transdermal delivery of sodium nonivamide acetate from volatile vehicles: Effects of polymers. Int J Pharm 1999; 176: 157-167.
107. Leichtnam ML, Rolland H, Wuthrich P, Guy RH. Formulation and evaluation of a testosterone transdermal spray. J Pharm Sci 2006; 95: 1693-1702.
108. Leichtnam ML, Rolland H, Wuthrich P, Guy RH. Impact of antinucleants on transdermal delivery of testosterone from a spray. J Pharm Sci 2007; 96: 84-92.